Wells Fargo & Company upgraded shares of Avidity Biosciences (NASDAQ:RNA – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday morning,Zacks.com reports. Several other equities analysts have also commented on RNA. Chardan Capital reissued a “neutral” rating and set a $72.00 price target on shares of Avidity Biosciences in [...]
Avidity Biosciences (NASDAQ:RNA) Upgraded at Wells Fargo & Company
